These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36518768)

  • 21. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
    Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
    Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
    Benonisson H; Altıntaş I; Sluijter M; Verploegen S; Labrijn AF; Schuurhuis DH; Houtkamp MA; Verbeek JS; Schuurman J; van Hall T
    Mol Cancer Ther; 2019 Feb; 18(2):312-322. PubMed ID: 30381448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
    King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
    Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
    de Gast GC; Haagen IA; van Houten AA; Klein SC; Duits AJ; de Weger RA; Vroom TM; Clark MR; Phillips J; van Dijk AJ
    Cancer Immunol Immunother; 1995 Jun; 40(6):390-6. PubMed ID: 7543021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
    Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
    Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
    Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
    Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
    Rossi EA; Rossi DL; Cardillo TM; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2014 Oct; 13(10):2341-51. PubMed ID: 25053819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
    Eguren-Santamaria I; Fernández de Piérola E; Camps G; Martín-Muñoz P; Campos M; Cuculescu D; Aguilera-Buenosvinos I; Rodríguez López I; Salido-Vallejo R; Alexandru R; De Andrea CE; Álvarez-Gigli L; Berraondo P; Melero I; Sanmamed MF
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells.
    Chen YJ; Chen M; Cheng TL; Tsai YS; Wang CH; Chen CY; Wu TY; Tzou SC; Wang KH; Cheng JJ; Kao AP; Lin SY; Chuang KH
    J Biomed Sci; 2023 May; 30(1):35. PubMed ID: 37259079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
    Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
    BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
    Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
    Li T; Niu M; Zhou J; Wu K; Yi M
    Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release.
    Lee E; Lee S; Park S; Son YG; Yoo J; Koh Y; Shin DY; Lim Y; Won J
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.